Stem definition | Drug id | CAS RN |
---|---|---|
sodium glucose co-transporter inhibitors, phlorizin derivatives | 4758 | 842133-18-0 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 1.19 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.74 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 10.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 29, 2013 | FDA | JANSSEN PHARMS | |
July 4, 2014 | PMDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diabetic ketoacidosis | 3135.73 | 20.60 | 754 | 10800 | 17456 | 46657052 |
Fungal infection | 2215.90 | 20.60 | 633 | 10921 | 28887 | 46645621 |
Genital infection fungal | 775.65 | 20.60 | 114 | 11440 | 75 | 46674433 |
Ketoacidosis | 502.37 | 20.60 | 129 | 11425 | 3826 | 46670682 |
Urinary tract infection | 380.09 | 20.60 | 361 | 11193 | 219905 | 46454603 |
Euglycaemic diabetic ketoacidosis | 316.82 | 20.60 | 78 | 11476 | 1938 | 46672570 |
Glycosylated haemoglobin increased | 232.42 | 20.60 | 91 | 11463 | 10785 | 46663723 |
Toe amputation | 218.25 | 20.60 | 58 | 11496 | 1966 | 46672542 |
Urine ketone body present | 168.91 | 20.60 | 48 | 11506 | 2094 | 46672414 |
Vulvovaginal mycotic infection | 162.54 | 20.60 | 55 | 11499 | 4296 | 46670212 |
Glomerular filtration rate decreased | 146.59 | 20.60 | 67 | 11487 | 11627 | 46662881 |
Blood glucose increased | 142.71 | 20.60 | 128 | 11426 | 71885 | 46602623 |
Weight decreased | 121.85 | 20.60 | 200 | 11354 | 210649 | 46463859 |
Diabetic foot infection | 119.62 | 20.60 | 23 | 11531 | 166 | 46674342 |
Pancreatitis | 114.05 | 20.60 | 91 | 11463 | 43536 | 46630972 |
Urine output increased | 103.14 | 20.60 | 29 | 11525 | 1216 | 46673292 |
Dehydration | 101.20 | 20.60 | 158 | 11396 | 159382 | 46515126 |
Metabolic acidosis | 99.46 | 20.60 | 80 | 11474 | 38700 | 46635808 |
Gangrene | 99.25 | 20.60 | 39 | 11515 | 4656 | 46669852 |
Vulvovaginal pruritus | 87.73 | 20.60 | 30 | 11524 | 2417 | 46672091 |
Pollakiuria | 79.67 | 20.60 | 58 | 11496 | 24203 | 46650305 |
Pyelonephritis | 65.19 | 20.60 | 43 | 11511 | 15314 | 46659194 |
Incorrect dose administered | 63.82 | 20.60 | 67 | 11487 | 45483 | 46629025 |
Product use issue | 63.07 | 20.60 | 96 | 11458 | 94548 | 46579960 |
Polyuria | 59.39 | 20.60 | 31 | 11523 | 7164 | 46667344 |
Ketosis | 57.80 | 20.60 | 15 | 11539 | 462 | 46674046 |
Osteomyelitis | 56.98 | 20.60 | 46 | 11508 | 22337 | 46652171 |
Foot amputation | 53.81 | 20.60 | 13 | 11541 | 297 | 46674211 |
Urosepsis | 51.06 | 20.60 | 37 | 11517 | 15316 | 46659192 |
Leg amputation | 50.24 | 20.60 | 19 | 11535 | 2044 | 46672464 |
Blood ketone body increased | 49.93 | 20.60 | 12 | 11542 | 268 | 46674240 |
Treatment noncompliance | 49.45 | 20.60 | 48 | 11506 | 29683 | 46644825 |
Adverse event | 49.16 | 20.60 | 51 | 11503 | 34133 | 46640375 |
Acidosis | 49.16 | 20.60 | 32 | 11522 | 11142 | 46663366 |
Vaginal infection | 46.74 | 20.60 | 25 | 11529 | 6068 | 46668440 |
Diabetic foot | 43.11 | 20.60 | 16 | 11538 | 1634 | 46672874 |
Off label use | 41.00 | 20.60 | 194 | 11360 | 379647 | 46294861 |
Hypoglycaemia | 37.40 | 20.60 | 56 | 11498 | 54293 | 46620215 |
Vulvovaginal candidiasis | 35.95 | 20.60 | 16 | 11538 | 2605 | 46671903 |
Pruritus genital | 35.69 | 20.60 | 11 | 11543 | 636 | 46673872 |
Dizziness | 33.21 | 20.60 | 169 | 11385 | 340245 | 46334263 |
Blood glucose decreased | 32.35 | 20.60 | 31 | 11523 | 18861 | 46655647 |
Rheumatoid arthritis | 31.73 | 20.60 | 10 | 11544 | 240205 | 46434303 |
Limb amputation | 31.38 | 20.60 | 5 | 11549 | 9 | 46674499 |
Anaemia | 29.83 | 20.60 | 13 | 11541 | 255766 | 46418742 |
Amputation | 29.14 | 20.60 | 7 | 11547 | 156 | 46674352 |
Ketonuria | 27.44 | 20.60 | 8 | 11546 | 382 | 46674126 |
Rash | 27.41 | 20.60 | 166 | 11388 | 356346 | 46318162 |
Acute kidney injury | 27.23 | 20.60 | 123 | 11431 | 235732 | 46438776 |
Glucose urine present | 27.09 | 20.60 | 9 | 11545 | 663 | 46673845 |
Thirst | 26.75 | 20.60 | 22 | 11532 | 10954 | 46663554 |
Anion gap increased | 26.72 | 20.60 | 11 | 11543 | 1480 | 46673028 |
Low density lipoprotein increased | 25.94 | 20.60 | 17 | 11537 | 5983 | 46668525 |
Genital rash | 25.74 | 20.60 | 8 | 11546 | 476 | 46674032 |
Micturition disorder | 25.48 | 20.60 | 11 | 11543 | 1665 | 46672843 |
Haemorrhagic erosive gastritis | 25.18 | 20.60 | 7 | 11547 | 281 | 46674227 |
Vulvovaginitis | 24.76 | 20.60 | 7 | 11547 | 299 | 46674209 |
Type 2 diabetes mellitus | 23.92 | 20.60 | 27 | 11527 | 19848 | 46654660 |
Necrotising fasciitis | 23.66 | 20.60 | 12 | 11542 | 2611 | 46671897 |
Pain | 23.60 | 20.60 | 52 | 11502 | 476896 | 46197612 |
Condition aggravated | 23.41 | 20.60 | 16 | 11538 | 245036 | 46429472 |
Renal abscess | 23.41 | 20.60 | 8 | 11546 | 643 | 46673865 |
Osteomyelitis acute | 22.69 | 20.60 | 6 | 11548 | 199 | 46674309 |
Pyrexia | 21.71 | 20.60 | 33 | 11521 | 348769 | 46325739 |
Creatinine renal clearance increased | 21.53 | 20.60 | 7 | 11547 | 482 | 46674026 |
Thrombocytopenia | 21.32 | 20.60 | 3 | 11551 | 126578 | 46547930 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diabetic ketoacidosis | 2264.33 | 21.30 | 615 | 10464 | 15371 | 29926028 |
Toe amputation | 689.31 | 21.30 | 161 | 10918 | 2080 | 29939319 |
Genital infection fungal | 574.96 | 21.30 | 93 | 10986 | 99 | 29941300 |
Fungal infection | 565.61 | 21.30 | 206 | 10873 | 13394 | 29928005 |
Diabetic foot infection | 326.28 | 21.30 | 71 | 11008 | 647 | 29940752 |
Balanoposthitis | 323.81 | 21.30 | 76 | 11003 | 1000 | 29940399 |
Osteomyelitis | 298.55 | 21.30 | 133 | 10946 | 14548 | 29926851 |
Ketoacidosis | 279.03 | 21.30 | 88 | 10991 | 3658 | 29937741 |
Euglycaemic diabetic ketoacidosis | 272.67 | 21.30 | 74 | 11005 | 1797 | 29939602 |
Urine output increased | 242.50 | 21.30 | 60 | 11019 | 998 | 29940401 |
Glycosylated haemoglobin increased | 222.21 | 21.30 | 95 | 10984 | 9396 | 29932003 |
Glomerular filtration rate decreased | 199.57 | 21.30 | 93 | 10986 | 11269 | 29930130 |
Gangrene | 180.80 | 21.30 | 67 | 11012 | 4547 | 29936852 |
Foot amputation | 166.55 | 21.30 | 38 | 11041 | 437 | 29940962 |
Pollakiuria | 161.95 | 21.30 | 92 | 10987 | 16814 | 29924585 |
Weight decreased | 157.18 | 21.30 | 233 | 10846 | 150688 | 29790711 |
Limb amputation | 155.78 | 21.30 | 25 | 11054 | 24 | 29941375 |
Leg amputation | 144.53 | 21.30 | 47 | 11032 | 2154 | 29939245 |
Urinary tract infection | 135.51 | 21.30 | 151 | 10928 | 73508 | 29867891 |
Urine ketone body present | 134.61 | 21.30 | 37 | 11042 | 942 | 29940457 |
Pancreatitis | 132.60 | 21.30 | 109 | 10970 | 36381 | 29905018 |
Amputation | 122.90 | 21.30 | 31 | 11048 | 559 | 29940840 |
Dehydration | 120.28 | 21.30 | 185 | 10894 | 123354 | 29818045 |
Diabetic foot | 119.17 | 21.30 | 43 | 11036 | 2702 | 29938697 |
Osteomyelitis acute | 113.10 | 21.30 | 23 | 11056 | 145 | 29941254 |
Blood glucose increased | 112.87 | 21.30 | 126 | 10953 | 61404 | 29879995 |
Skin ulcer | 94.02 | 21.30 | 68 | 11011 | 18781 | 29922618 |
Metabolic acidosis | 81.45 | 21.30 | 84 | 10995 | 37377 | 29904022 |
Ketonuria | 74.65 | 21.30 | 21 | 11058 | 583 | 29940816 |
Lactic acidosis | 64.27 | 21.30 | 68 | 11011 | 31145 | 29910254 |
Blood ketone body increased | 60.16 | 21.30 | 16 | 11063 | 358 | 29941041 |
Ketosis | 59.87 | 21.30 | 16 | 11063 | 365 | 29941034 |
Prostatitis | 58.83 | 21.30 | 31 | 11048 | 4876 | 29936523 |
Glucose urine present | 57.62 | 21.30 | 19 | 11060 | 909 | 29940490 |
Adverse event | 56.01 | 21.30 | 46 | 11033 | 15295 | 29926104 |
Polyuria | 52.32 | 21.30 | 33 | 11046 | 7273 | 29934126 |
Thirst | 51.30 | 21.30 | 32 | 11047 | 6917 | 29934482 |
Cellulitis | 46.67 | 21.30 | 71 | 11008 | 46713 | 29894686 |
Genital infection | 45.80 | 21.30 | 8 | 11071 | 18 | 29941381 |
Incorrect dose administered | 44.97 | 21.30 | 57 | 11022 | 31629 | 29909770 |
Dizziness | 41.62 | 21.30 | 162 | 10917 | 194747 | 29746652 |
Cerebral infarction | 41.54 | 21.30 | 50 | 11029 | 26323 | 29915076 |
Renal pain | 41.15 | 21.30 | 20 | 11059 | 2652 | 29938747 |
Anaemia | 39.26 | 21.30 | 14 | 11065 | 207978 | 29733421 |
Gas gangrene | 38.86 | 21.30 | 8 | 11071 | 54 | 29941345 |
Treatment noncompliance | 38.35 | 21.30 | 47 | 11032 | 25206 | 29916193 |
Hypoglycaemia | 38.18 | 21.30 | 68 | 11011 | 50913 | 29890486 |
Product use issue | 37.89 | 21.30 | 64 | 11015 | 45952 | 29895447 |
Acute kidney injury | 37.11 | 21.30 | 199 | 10880 | 273643 | 29667756 |
Phimosis | 35.28 | 21.30 | 12 | 11067 | 632 | 29940767 |
Blood creatinine increased | 35.09 | 21.30 | 93 | 10986 | 91282 | 29850117 |
Thrombocytopenia | 34.20 | 21.30 | 5 | 11074 | 137039 | 29804360 |
Diabetic ulcer | 33.28 | 21.30 | 8 | 11071 | 117 | 29941282 |
Dysuria | 32.69 | 21.30 | 41 | 11038 | 22500 | 29918899 |
Microalbuminuria | 31.59 | 21.30 | 11 | 11068 | 622 | 29940777 |
Blood ketone body | 31.56 | 21.30 | 7 | 11072 | 70 | 29941329 |
Osteomyelitis chronic | 31.23 | 21.30 | 9 | 11070 | 273 | 29941126 |
Pyrexia | 31.14 | 21.30 | 38 | 11041 | 294451 | 29646948 |
Death | 31.02 | 21.30 | 53 | 11026 | 357230 | 29584169 |
Neuropathic arthropathy | 30.93 | 21.30 | 8 | 11071 | 160 | 29941239 |
Hyperkalaemia | 30.38 | 21.30 | 72 | 11007 | 65938 | 29875461 |
Acetonaemia | 30.10 | 21.30 | 7 | 11072 | 88 | 29941311 |
Toxicity to various agents | 30.05 | 21.30 | 14 | 11065 | 177169 | 29764230 |
Penile infection | 29.90 | 21.30 | 6 | 11073 | 35 | 29941364 |
Genital rash | 29.73 | 21.30 | 10 | 11069 | 509 | 29940890 |
Neutropenia | 29.20 | 21.30 | 6 | 11073 | 128534 | 29812865 |
Glycosylated haemoglobin decreased | 29.01 | 21.30 | 9 | 11070 | 353 | 29941046 |
Micturition disorder | 28.96 | 21.30 | 14 | 11065 | 1835 | 29939564 |
Urinary tract infection fungal | 28.51 | 21.30 | 9 | 11070 | 374 | 29941025 |
Diabetic gangrene | 28.40 | 21.30 | 8 | 11071 | 223 | 29941176 |
Necrotising fasciitis | 28.31 | 21.30 | 17 | 11062 | 3432 | 29937967 |
Therapeutic response increased | 27.50 | 21.30 | 8 | 11071 | 251 | 29941148 |
Extremity necrosis | 27.34 | 21.30 | 13 | 11066 | 1642 | 29939757 |
Nephrolithiasis | 26.65 | 21.30 | 39 | 11040 | 24771 | 29916628 |
Drug interaction | 26.55 | 21.30 | 21 | 11058 | 199547 | 29741852 |
Rash | 24.27 | 21.30 | 137 | 10942 | 191752 | 29749647 |
Skin injury | 23.32 | 21.30 | 10 | 11069 | 993 | 29940406 |
Urosepsis | 23.17 | 21.30 | 24 | 11055 | 10708 | 29930691 |
Diabetes mellitus inadequate control | 23.10 | 21.30 | 26 | 11053 | 12736 | 29928663 |
Pruritus genital | 22.84 | 21.30 | 8 | 11071 | 460 | 29940939 |
Haemoglobin decreased | 22.68 | 21.30 | 7 | 11072 | 114091 | 29827308 |
Urine ketone body | 22.03 | 21.30 | 5 | 11074 | 56 | 29941343 |
Source | Code | Description |
---|---|---|
ATC | A10BD16 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BK02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
MeSH PA | D007004 | Hypoglycemic Agents |
MeSH PA | D000077203 | Sodium-Glucose Transporter 2 Inhibitors |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
FDA MoA | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors |
FDA EPC | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor |
CHEBI has role | CHEBI:35526 | hypoglycemic drug |
CHEBI has role | CHEBI:73273 | sodium glucose co-transporter 2 inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.62 | acidic |
pKa2 | 13.26 | acidic |
pKa3 | 13.7 | acidic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG | INVOKANULL | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
300MG | INVOKANULL | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 29, 2021 | NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD) |
100MG | INVOKANULL | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | Sept. 27, 2022 | TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY |
300MG | INVOKANULL | JANSSEN PHARMS | N204042 | March 29, 2013 | RX | TABLET | ORAL | Sept. 27, 2022 | TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 8.66 | WOMBAT-PK | CHEMBL | |||
Sodium/glucose cotransporter 1 | Transporter | IC50 | 5.72 | CHEMBL | |||||
Protease | Enzyme | Ki | 6.20 | CHEMBL |
ID | Source |
---|---|
D09592 | KEGG_DRUG |
928672-86-0 | SECONDARY_CAS_RN |
4032289 | VANDF |
C2974540 | UMLSCUI |
CHEBI:73272 | CHEBI |
CHEMBL2048484 | ChEMBL_ID |
CHEMBL4594217 | ChEMBL_ID |
CHEMBL2103841 | ChEMBL_ID |
DB08907 | DRUGBANK_ID |
D000068896 | MESH_DESCRIPTOR_UI |
9225 | INN_ID |
24812758 | PUBCHEM_CID |
4582 | IUPHAR_LIGAND_ID |
0SAC974Z85 | UNII |
1373458 | RXNORM |
200558 | MMSL |
29373 | MMSL |
d08080 | MMSL |
014959 | NDDF |
703676004 | SNOMEDCT_US |
703681008 | SNOMEDCT_US |
725664009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4364 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5029 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5033 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5034 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 29 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-140 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-141 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 30 sections |
INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-540 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-541 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 34 sections |
INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-542 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-543 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 34 sections |
INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-940 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 34 sections |
INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-941 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 34 sections |
INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-942 | TABLET, FILM COATED, EXTENDED RELEASE | 150 mg | ORAL | NDA | 34 sections |
INVOKAMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50458-943 | TABLET, FILM COATED, EXTENDED RELEASE | 150 mg | ORAL | NDA | 34 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-1425 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 30 sections |
INVOKANULL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-1426 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 30 sections |
INVOKAMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-8260 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 31 sections |